Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-09-28Clinical Trial Update: Adapting Critical Time Intervention to Support Inpatient Medical Care Transition [NA]
A clinical trial update on adapting Critical Time Intervention to support inpatient medical care transitions, with termination as the status…
-
CLINICAL_TRIALS trial_result · 2021-09-22Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia [Phase 2]
Phase 2 study evaluating the efficacy and safety of SEP-363856 in acutely psychotic adults with schizophrenia has completed and posted resul…
-
CLINICAL_TRIALS trial_result · 2021-09-22Clinical Trial Update: A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms [Phase 2]
Phase 2 clinical trial update for LY2140023 in schizophrenia patients with prominent negative symptoms has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-09-16Clinical Trial Update: A Physical Dependence Study in Schizophrenia [Phase 3]
Phase 3 clinical trial evaluating physical dependence in schizophrenia; study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-09-14Clinical Trial Update: A Study in Schizophrenic Patients [Phase 2]
Phase 2 clinical trial in schizophrenia was terminated; results posted in 2021.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-09-14Clinical Trial Update: A Study of Safety and Tolerability in Subjects With Schizophrenia [Phase 1]
Phase 1 trial assessing safety and tolerability in subjects with schizophrenia has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-09-13Clinical Trial Update: An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults [Phase 2, Phase 3]
Adaptive Phase II/III study evaluating NaBen as add-on therapy to clozapine for residual symptoms in adults with refractory schizophrenia; c…
-
CLINICAL_TRIALS trial_result · 2021-09-09Clinical Trial Update: Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction [NA]
Clinical trial assessing the relationship between cognitive function and relapse in schizophrenia when dose is reduced; results posted after…
-
CLINICAL_TRIALS trial_result · 2021-09-08Clinical Trial Update: A Study of ALKS 3831 in Adults With Schizophrenia [Phase 2]
Phase 2 trial update for ALKS 3831 in adults with schizophrenia has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-09-05Clinical Trial Update: A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite® [Phase 3]
Phase 3 trial examining Abilify MyCite in adults with schizophrenia was terminated; results posted.
-
FDA approval · 2021-08-31FDA Approved: RISPERIDONE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approves a supplemental application for risperidone by Amneal Pharmaceuticals LLC. This action represents a supplemental approval under …
-
FDA approval · 2021-08-30FDA Approved: INVEGA HAFYERA — Supplemental Application (Janssen Pharmaceuticals, Inc)
The FDA approved a supplemental application for Invega Hafyera (paliperidone palmitate) to expand its label for the long-acting injectable t…
-
CLINICAL_TRIALS trial_result · 2021-08-26Clinical Trial Update: Tryptophan MRI in People With Schizophrenia and Healthy Controls [Phase 2, Phase 3]
Phase 2/3 clinical trial evaluating tryptophan MRI in people with schizophrenia and healthy controls has completed, with results posted in 2…
-
FDA approval · 2021-08-24FDA Approved: LURASIDONE HYDROCHLORIDE — Original Application (Torrent Pharmaceuticals Limited)
FDA approves Torrent Pharmaceuticals Limited's original application for lurasidone hydrochloride tablets as a generic treatment for schizoph…
-
FDA approval · 2021-08-23FDA Approved: HALOPERIDOL DECANOATE — Supplemental Application (Mylan Institutional LLC)
FDA approves a supplemental application for HALOPERIDOL DECANOATE from Mylan Institutional LLC, confirming a generic long-acting injectable …
-
CLINICAL_TRIALS trial_result · 2021-08-20Clinical Trial Update: Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo [Phase 2]
Phase 2 trial comparing LY2140023, olanzapine, and placebo in schizophrenia has completed.
-
CLINICAL_TRIALS trial_result · 2021-08-16Clinical Trial Update: Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia. [Phase 2]
Phase 2 trial update for pharmacologically-augmented cognitive therapies (PACTs) in schizophrenia has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-08-13Clinical Trial Update: Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia [Phase 3]
Phase 3 trial update examining whether adding ondansetron to ongoing antipsychotic therapy improves outcomes in schizophrenia; study complet…
-
CLINICAL_TRIALS trial_result · 2021-08-10Clinical Trial Update: Motivation and Skills Support (MASS) [NA]
Clinical trial update for the MASS study (K03404219) completed; results posted in 2021.
-
FDA approval · 2021-08-09FDA Approved: INVEGA SUSTENNA — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved a supplemental application for INVEGA SUSTENNA (paliperidone palmitate) from Janssen Pharmaceuticals, Inc.
-
FDA approval · 2021-08-09FDA Approved: INVEGA HAFYERA — Supplemental Application (Janssen Pharmaceuticals, Inc)
FDA approved a supplemental application for INVEGA HAFYERA (paliperidone palmitate) from Janssen Pharmaceuticals, Inc.
-
CLINICAL_TRIALS trial_result · 2021-08-06Clinical Trial Update: Insight Enhancement Program vs. Metacognitive Training for Psychosis in Patients With Schizophrenia: A Three-Armed Comparative Randomized Controlled Trial [Phase 3]
A phase 3 randomized controlled trial comparing Insight Enhancement Program to Metacognitive Training for psychosis in schizophrenia spectru…
-
CLINICAL_TRIALS trial_result · 2021-08-05Clinical Trial Update: Pharmacologic Modulation of Hippocampal Activity in Psychosis [Phase 2]
Phase 2 trial investigating pharmacologic modulation of hippocampal activity in schizophrenia/psychosis; study terminated with posted result…
-
CLINICAL_TRIALS trial_result · 2021-08-04Clinical Trial Update: Cognitive Behaviour Therapy for Voices and Dissociation [Phase 2]
Phase 2 trial update for cognitive behavioral therapy targeting voices and dissociation in schizophrenia and related conditions; study compl…
-
FDA approval · 2021-07-29FDA Approved: CLOZAPINE — Supplemental Application (Accord Healthcare Inc.)
FDA approved a supplemental application for clozapine from Accord Healthcare Inc. (generic clozapine). The approval pertains to a supplement…